Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic
- 26 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Archives of Osteoporosis
- Vol. 16 (1), 1-3
- https://doi.org/10.1007/s11657-021-00904-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Persistence and adherence to parenteral osteoporosis therapies: a systematic reviewOsteoporosis International, 2020
- Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultation?Osteoporosis International, 2020
- Managing common endocrine disorders amid COVID-19 pandemicDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiationBone Reports, 2020
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTSBone, 2017
- Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and BelgiumArchives of Osteoporosis, 2017
- Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesJournal of Bone and Mineral Research, 2017
- Prolonged Bisphosphonate Release after Treatment in ChildrenThe New England Journal of Medicine, 2007